What's new in the prevention and therapy of fetal growth restriction? Role of nitric oxide

Abstract

R.S. Osipov1, P.A. Kuznetsov2, L.S. Dzhokhadze2, I.O. Shuginin1 1Moscow Regional Research Institute of Obstetrics and Gynecology, Moscow, Russian Federation 2Pirogov Russian National Research Medical University, Moscow, Russian Federation Fetal growth restriction (FGR) is an integral term for a group of conditions in which the fetus does not reach the size potentially embedded in its genome. FGR is the main cause of perinatal mortality. Commonly, FGR develops due to placental insufficiency. At the same time, there are very few levers of control on this pathology by obstetricians and gynecologists. The authors present preclinical and clinical study review concerning drugs for the FGR prevention and its therapy, as well as the role of nitric oxide (NO). Currently, it is possible to determine the risk group based on the history and data fr om the first trimester screening, as well as to use acetylsalicylic acid (ASA) for the preventive measures. During the study, there are several drugs that can potentially not only prevent FGR but also improve the condition course with, when the diagnose is already established. Conducting randomized clinical trials, wh ere the primary endpoint would be the FGR, will allow to assess the safety and efficacy of the proposed medicines and advance them into clinical practice. Keywords: fetal growth restriction, prevention, acetylsalicylic acid, nitric oxide, randomized clinical trials, small for gestational age. For citation: Osipov R.S., Kuznetsov P.A., Dzhokhadze L.S., Shuginin I.O. What's new in the prevention and therapy of fetal growth restriction? Role of nitric oxide. Russian Journal of Woman and Child Health. 2023;6(3):258–264 (in Russ.). DOI: 10.32364/2618-8430-2023-6-3-7.